Alan M. Tennenberg

1.3k total citations
21 papers, 951 citations indexed

About

Alan M. Tennenberg is a scholar working on Epidemiology, Pharmacology and Molecular Medicine. According to data from OpenAlex, Alan M. Tennenberg has authored 21 papers receiving a total of 951 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 11 papers in Pharmacology and 9 papers in Molecular Medicine. Recurrent topics in Alan M. Tennenberg's work include Pneumonia and Respiratory Infections (12 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers) and Antibiotic Resistance in Bacteria (9 papers). Alan M. Tennenberg is often cited by papers focused on Pneumonia and Respiratory Infections (12 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers) and Antibiotic Resistance in Bacteria (9 papers). Alan M. Tennenberg collaborates with scholars based in United States and United Kingdom. Alan M. Tennenberg's co-authors include James B. Kahn, Neringa Zadeikis, Mohammed M. Khashab, Barbara A. Wiesinger, Jim Xiang, Lala M. Dunbar, Leon G. Smith, Michael P. Habib, Richard G. Wunderink and Shu‐Chen Wu and has published in prestigious journals such as Annals of Internal Medicine, Clinical Infectious Diseases and CHEST Journal.

In The Last Decade

Alan M. Tennenberg

21 papers receiving 908 citations

Peers

Countries citing papers authored by Alan M. Tennenberg

Since Specialization

Citations

This map shows the geographic impact of Alan M. Tennenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan M. Tennenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan M. Tennenberg more than expected).

Fields of papers citing papers by Alan M. Tennenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan M. Tennenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan M. Tennenberg. The network helps show where Alan M. Tennenberg may publish in the future.

Co-authorship network of co-authors of Alan M. Tennenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Alan M. Tennenberg. A scholar is included among the top collaborators of Alan M. Tennenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan M. Tennenberg. Alan M. Tennenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sex-Based Outcomes of Darunavir–Ritonavir Therapy: The GRACE (Gender, Race, and Clinical Experience) Study 2010 ·Annals of Internal Medicine ·Judith S. Currier, (unknown), Debbie Hagins, Carmen Zorrilla, Judith Feinberg, Robert J. Ryan, (unknown), Alan M. Tennenberg, Joseph Mrus, Kathleen Squires	6
2	Sex-Based Outcomes of Darunavir-Ritonavir Therapy 2010 ·Annals of Internal Medicine ·Judith S. Currier, (unknown), Debbie Hagins, Carmen Zorrilla, Judith Feinberg, Robert J. Ryan, (unknown), Alan M. Tennenberg, Joseph Mrus, Kathleen Squires	2
3	GRACE (Gender, Race And Clinical Experience): Outcomes by Race at Week 48 2009 ·Kimberly Y. Smith, (unknown), Robert J. Ryan, (unknown), Alan M. Tennenberg, Joseph Mrus	3
4	Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients 2006 ·Respiratory Medicine ·Andrew F. Shorr, Mohammed M. Khashab, Jim Xiang, Alan M. Tennenberg, James B. Kahn	32
5	Pneumonia due to Pseudomonas aeruginosa:the levofloxacin clinical trials experience 2006 ·Current Medical Research and Opinion ·Alan M. Tennenberg, (unknown), Shu‐Chen Wu, James B. Kahn	12
6	Pneumonia due to Pseudomonas aeruginosa: the Levofloxacin Clinical Trials Experience 2006 ·Current Medical Research and Opinion ·Alan M. Tennenberg, (unknown), Shu‐Chen Wu, James G. Kahn	1
7	Lowering the Dose of Hydroxyurea Minimizes Toxicity and Maximizes Anti-HIV Potency 2005 ·AIDS Research and Human Retroviruses ·Franco Lori, Richard B. Pollard, Lucia Whitman, Nyasha Bakare, Gary Blick, (unknown), Andrea Foli, D. M. Peterson, Alan M. Tennenberg, Shannon Schrader, Bruce Rashbaum, Charles Farthing, (unknown), D. B. Norris, (unknown), Ian Frank, (unknown), (unknown), David M. Asmuth, Julianna Lisziewicz	9
8	Levofloxacin for Treatment of Ventilator-Associated Pneumonia: A Subgroup Analysis from a Randomized Trial 2005 ·Clinical Infectious Diseases ·Andrew F. Shorr, Neringa Zadeikis, William L. Jackson, (unknown), Shu-Chen Wu, Alan M. Tennenberg, Marin H. Kollef	26
9	A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged ≥65 years with community-acquired pneumonia 2005 ·Clinical Therapeutics ·Andrew F. Shorr, Neringa Zadeikis, Jim Xiang, Alan M. Tennenberg, E. Wes Ely	35
10	Levofloxacin Efficacy in the Treatment of Community-Acquired Legionellosis 2004 ·CHEST Journal ·Victor L. Yu, Richard N. Greenberg, Neringa Zadeikis, Janet E. Stout, Mohammed M. Khashab, William H. Olson, Alan M. Tennenberg	71
11	Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia 2004 ·Current Medical Research and Opinion ·Thomas M. File, Gary Milkovich, Alan M. Tennenberg, Jim Xiang, Mohammed M. Khashab, Neringa Zadeikis	26
12	Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens 2004 ·Current Medical Research and Opinion ·Lala M. Dunbar, Mohammed M. Khashab, James B. Kahn, Neringa Zadeikis, Jim Xiang, Alan M. Tennenberg	68
13	Multicenter, Postmarketing Assessment of Levofloxacin in the Treatment of Adults with Community-Acquired Pneumonia 2004 ·Clinical Infectious Diseases ·Basil Akpunonu, (unknown), (unknown), Alan M. Tennenberg, Barbara A. Wiesinger, Rezaul Karim, (unknown), James B. Kahn	17
14	Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study 2003 ·Clinical Therapeutics ·Mike West, Bernard R. Boulanger, Charles Fogarty, Alan M. Tennenberg, Barbara A. Wiesinger, (unknown), Shu‐Chen Wu, Cynthia L. Fowler, Nancy Morgan, James B. Kahn	89
15	Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study 2003 ·Urology ·(unknown), (unknown), Paul S. Ray, William M. Schiff, Alan M. Tennenberg, Barbara A. Wiesinger, Pamela A. Wright, Shu‐Chen Wu, Neringa Zadeikis, James B. Kahn	92
16	High‐Dose, Short‐Course Levofloxacin for Community‐Acquired Pneumonia: A New Treatment Paradigm 2003 ·Clinical Infectious Diseases ·Lala M. Dunbar, Richard G. Wunderink, Michael P. Habib, Leon G. Smith, Alan M. Tennenberg, Mohammed M. Khashab, Barbara A. Wiesinger, Jim Xiang, Neringa Zadeikis, James B. Kahn	250
17	A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia 2002 ·Clinical Therapeutics ·(unknown), Jing Liu, Gary T. Kinasewitz, Gregory J. Moran, (unknown), William H. Olson, (unknown), (unknown), (unknown), Barbara A. Wiesinger, Alan M. Tennenberg, James B. Kahn	74
18	Outbreak in a New York City Teaching Hospital Burn Center Caused by the Iberian Epidemic Clone of MRSA 1998 ·Microbial Drug Resistance ·Richard B. Roberts, Alan M. Tennenberg, William Eisner, (unknown), Lewis M. Drusin, Roger W. Yurt, Barry N. Kreiswirth	44
19	Varicella Vaccination for Healthcare Workers at a University Hospital An Analysis of Costs and Benefits 1997 ·Infection Control and Hospital Epidemiology ·Alan M. Tennenberg, (unknown), (unknown), Lewis M. Drusin	29
20	Varicella Vaccination for Healthcare Workers at a University Hospital: An Analysis of Costs and Benefits 1997 ·Infection Control and Hospital Epidemiology ·Alan M. Tennenberg, (unknown), (unknown), Lewis M. Drusin	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact